“Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch Vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison”. SKIN The Journal of Cutaneous Medicine 10, no. 2 (March 10, 2026): s738. Accessed May 2, 2026. https://skin.dermsquared.com/skin/article/view/4061.